Abstract: Described herein are methods for purification of biological material using high gradient magnetic separation. For example, a method includes: providing a ferromagnetic matrix surrounded by a separation column, the separation column including an elongate body defining a lumen having an inlet and an outlet; applying an external magnetic field to the separation column; saturating unspecific binding sites in the ferromagnetic matrix by applying a buffer solution to the ferromagnetic matrix; and introducing biological material into the lumen of the separation column. In some embodiments, the ferromagnetic matrix is uncoated, and the buffer solution includes at least one macromolecule. In some embodiments, the method further includes incubating the ferromagnetic matrix with the buffer solution for at least three minutes to equilibrate the ferromagnetic matrix.

Abstract: Described herein are methods for purification of biological material using high gradient magnetic separation. For example, a method includes: providing a ferromagnetic matrix surrounded by a separation column, the separation column including an elongate body defining a lumen having an inlet and an outlet; applying an external magnetic field to the separation column; saturating unspecific binding sites in the ferromagnetic matrix by applying a buffer solution to the ferromagnetic matrix; and introducing biological material into the lumen of the separation column. In some embodiments, the ferromagnetic matrix is uncoated, and the buffer solution includes at least one macromolecule. In some embodiments, the method further includes incubating the ferromagnetic matrix with the buffer solution for at least three minutes to equilibrate the ferromagnetic matrix.

Abstract: Use of the large form of human 2?,5?-Oligoadenylate Synthetase (OAS3) for diagnosis, prevention and treatment of infection with positive-sense single-stranded RNA viruses and for prediction of human genetic susceptibility to positive-sense single-stranded RNA virus-related diseases.

Abstract: The invention relates to a high gradient magnet separation device for the separation or purification of magnetic or magnetically labeled biological material, comprising a magnet, a separating column, and a ferromagnetic matrix that can be arranged in an interior chamber of the separating column, and a storage container containing a buffer solution for the equilibration of the separating column and/or for the suspension of the biological material, wherein during operation a magnetic field created by the magnet creates a high gradient magnetic filed in the matrix and buffer solution can flow from the storage container through the separating column. For this purpose, the buffer solution comprises a base solution and macromolecules that can saturate nonspecific binding sites of the matrix.

Abstract: The invention includes a genetic construct and a mutant dengue virus, designated as strain MBU 01-2002, which is a mutant dengue virus generated by genetic modification of the 13-amino acid sequence just proximal to the pr-M junction within the prM coding region of the genome. The modification involves increasing the number of positively charged amino acids and abolishing the negatively charged amino acids in this pr-M junction sequence. The mutant dengue virus strain MBU 01-2002 possesses less prM protein on the viral envelope than the prototype dengue virus, is capable of inducing infected C6/36 cells to fuse at neutral pH, is as efficient as the prototype virus in the intracellular multiplication, but is defective in its release from infected cells.

Abstract: The present specification discloses methods of determining risk of developing Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) in an individual infected with dengue virus (DV). The methods comprise determining, in a fluid or tissue sample of an individual, the presence, absence or quantity of dengue virus protein NS1, and determining, in a fluid or tissue sample of the individual, presence, absence or quantity of SC5b-9 complement complex. The methods can further comprise comparing the levels of NS1 protein and SC5b-9 complement complex with a database comprising epidemiological data correlating levels of NS1 protein and SC5b-9 complement complex with probability of developing DHF/DSS in a population.

Abstract: The invention includes a genetic construct and a mutant dengue virus, designated as strain MBU 01-2002, which is a mutant dengue virus generated by genetic modification of the 13-amino acid sequence just proximal to the pr-M junction within the prM coding region of the genome. The modification involves increasing the number of positively charged amino acid and abolishing the negatively charged amino acid in this pr-M junction sequence. The mutant dengue virus strain MBU 01-2002 possesses less prM protein on the viral envelope than the prototype dengue virus, is capable of inducing infected C6/36 cells to fuse at neutral pH, is as efficient as the prototype virus in the intracellular multiplication, but is defective in its release from infected cells.

Abstract: The present specification discloses methods of determining risk of developing Dengue Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) in an individual infected with dengue virus (DV). The methods comprise determining, in a fluid or tissue sample of an individual, the presence, absence or quantity of dengue virus protein NS1, and determining, in a fluid or tissue sample of the individual, presence, absence or quantity of SC5b-9 complement complex. The methods can further comprise comparing the levels of NS1 protein and SC5b-9 complement complex with a database comprising epidemiological data correlating levels of NS1 protein and SC5b-9 complement complex with probability of developing DHF/DSS in a population.